These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30406939)

  • 21. Complications in recipients of cardioverter-defibrillator or cardiac resynchronization therapy: Insights from Silesian Center Defibrillator registry.
    Tajstra M; Gadula-Gacek E; Kurek A; Adamowicz-Czoch E; Olszowski D; Ostręga M; Ciślak A; Pyka Ł; Hawranek M; Lekston A; Poloński L; Gąsior M
    Cardiol J; 2017; 24(5):515-522. PubMed ID: 27734455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of expanding evidence and evolving clinical guidelines on the prevalence of indication for cardiac resynchronization therapy in patients with heart failure.
    Lund LH; Svennblad B; Dahlström U; Ståhlberg M
    Eur J Heart Fail; 2018 Apr; 20(4):769-777. PubMed ID: 28949083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac resynchronisation therapy in patients with chronic heart failure.
    Lalani GG; Birgersdotter-Green U
    Heart; 2015 Jul; 101(13):1008-14. PubMed ID: 25882504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. European cardiac resynchronization therapy survey II: rationale and design.
    Dickstein K; Normand C; Anker SD; Auricchio A; Blomström-Lundqvisit C; Bogale N; Cleland J; Filippatos G; Gasparini M; Gitt A; Hindricks G; Kuck KH; Ponikowski P; Stellbrink C; Ruschitzka F; Linde C
    Europace; 2015 Jan; 17(1):137-41. PubMed ID: 25414481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sex-specific outcomes with addition of defibrillation to resynchronisation therapy in patients with heart failure.
    Barra S; Providência R; Duehmke R; Boveda S; Marijon E; Reitan C; Borgquist R; Klug D; Defaye P; Sadoul N; Deharo JC; Sadien I; Patel K; Looi KL; Begley D; Chow AW; Le Heuzey JY; Agarwal S;
    Heart; 2017 May; 103(10):753-760. PubMed ID: 28104669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Success rate of transvenous left ventricular lead implantation for cardiac resynchronisation therapy - recent experience of a single centre.
    Sterliński M; Maciag A; Kowalik I; Lewandowski M; Zajac D; Syska P; Sosnowski C; Labecka A; Kuśmierski K; Pytkowski M; Szwed H
    Kardiol Pol; 2010 Aug; 68(8):903-9. PubMed ID: 20730721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of cardiac resynchronisation therapy in the treatment of end-stage inotrope-dependent heart failure patients.
    Sokal A; Jędrzejczyk E; Lenarczyk R; Pluta S; Kowalski O; Pruszkowska P; Mazurek M; Swiątkowski A; Kalarus Z
    Kardiol Pol; 2014; 72(9):777-82. PubMed ID: 24846358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival and Heart Failure Hospitalization in Patients With Cardiac Resynchronization Therapy With or Without a Defibrillator for Primary Prevention in Japan　- Analysis of the Japan Cardiac Device Treatment Registry Database.
    Yokoshiki H; Shimizu A; Mitsuhashi T; Furushima H; Sekiguchi Y; Manaka T; Nishii N; Ueyama T; Morita N; Okamura H; Nitta T; Hirao K; Okumura K;
    Circ J; 2017 Nov; 81(12):1798-1806. PubMed ID: 28626201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time course of secondary mitral regurgitation in patients with heart failure receiving cardiac resynchronization therapy: Impact on long-term outcome beyond left ventricular reverse remodelling.
    Binda C; Menet A; Appert L; Ennezat PV; Delelis F; Castel AL; Le Goffic C; Guyomar Y; Ringlé A; Guerbaai RA; Graux P; Tribouilloy C; Maréchaux S
    Arch Cardiovasc Dis; 2018 May; 111(5):320-331. PubMed ID: 29102366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator.
    Martens P; Verbrugge FH; Nijst P; Dupont M; Nuyens D; Herendael HV; Rivero-Ayerza M; Tang WH; Mullens W
    Heart; 2017 Dec; 103(24):1977-1984. PubMed ID: 28716973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cardiac resynchronisation].
    Barthez O
    Soins; 2017 Nov; 62(820):32-34. PubMed ID: 29153215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Approach to cardiac resyncronization therapy.
    Dobreanu D; Dagres N; Svendsen JH; Marinskis G; Bongiorni MG; Blomström-Lundqvist C
    Europace; 2012 Sep; 14(9):1359-62. PubMed ID: 22930718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF.
    Wilcox JE; Fonarow GC; Zhang Y; Albert NM; Curtis AB; Gheorghiade M; Heywood JT; Mehra MR; O'Connor CM; Reynolds D; Walsh MN; Yancy CW
    Circ Heart Fail; 2014 Jan; 7(1):146-53. PubMed ID: 24178311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk stratification in patients with cardiac resynchronisation therapy: the AL-FINE CRT risk score.
    Kisiel R; Fijorek K; Sondej T; Pavlinec C; Kukla P; Czarnecka D; Jastrzębski M
    Kardiol Pol; 2018; 76(10):1441-1449. PubMed ID: 30251245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of cardiac resynchronisation therapy in patients with wide QRS and non-specific intraventricular conduction delay: rationale and design of the multicentre randomised NICD-CRT study.
    Eschalier R; Ploux S; Pereira B; Clémenty N; Da Costa A; Defaye P; Garrigue S; Gourraud JB; Gras D; Guy-Moyat B; Leclercq C; Mondoly P; Bordachar P
    BMJ Open; 2016 Nov; 6(11):e012383. PubMed ID: 27836874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure.
    Linde C; Ståhlberg M; Benson L; Braunschweig F; Edner M; Dahlström U; Alehagen U; Lund LH
    Europace; 2015 Mar; 17(3):424-31. PubMed ID: 25164429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Replacement of implantable cardioverter defibrillators and cardiac resynchronization therapy devices: results of the European Heart Rhythm Association survey.
    Tilz R; Boveda S; Deharo JC; Dobreanu D; Haugaa KH; Dagres N
    Europace; 2016 Jun; 18(6):945-9. PubMed ID: 27297231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.
    Khazanie P; Greiner MA; Al-Khatib SM; Piccini JP; Turakhia MP; Varosy PD; Masoudi FA; Curtis LH; Hernandez AF;
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of quadripolar LV leads on heart failure hospitalization rates among patients implanted with CRT-D: data from the Israeli ICD Registry.
    Leshem E; Suleiman M; Laish-Farkash A; Haim M; Geist M; Luria D; Glikson M; Goldenberg I; Michowitz Y;
    J Interv Card Electrophysiol; 2018 Jan; 51(1):5-12. PubMed ID: 29274032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker.
    Schuchert A; Muto C; Maounis T; Frank R; Boulogne E; Polauck A; Padeletti L;
    Europace; 2013 Jan; 15(1):71-6. PubMed ID: 22927665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.